The Medicines Company Company Profile (NASDAQ:MDCO)

About The Medicines Company (NASDAQ:MDCO)

The Medicines Company logoThe Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Generic Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:MDCO
  • CUSIP: 58468810
  • Web: www.themedicinescompany.com
Capitalization:
  • Market Cap: $2.57434 billion
  • Outstanding Shares: 71,917,000
Average Prices:
  • 50 Day Moving Avg: $36.16
  • 200 Day Moving Avg: $42.45
  • 52 Week Range: $30.80 - $55.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.92
  • P/E Growth: -0.05
Sales & Book Value:
  • Annual Revenue: $105.76 million
  • Price / Sales: 24.61
  • Book Value: $1.99 per share
  • Price / Book: 18.21
Profitability:
  • EBIDTA: ($300,670,000.00)
  • Net Margins: -670.46%
  • Return on Equity: -137.20%
  • Return on Assets: -45.68%
Debt:
  • Debt-to-Equity Ratio: 2.14%
  • Current Ratio: 0.85%
  • Quick Ratio: 0.71%
Misc:
  • Average Volume: 1.20 million shs.
  • Beta: 0.86
  • Short Ratio: 19.83
 

Frequently Asked Questions for The Medicines Company (NASDAQ:MDCO)

What is The Medicines Company's stock symbol?

The Medicines Company trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines Company's earnings last quarter?

The Medicines Company (NASDAQ:MDCO) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($5.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.29) by $4.23. The business had revenue of $18.74 million for the quarter, compared to analysts' expectations of $29.64 million. The Medicines Company had a negative return on equity of 137.20% and a negative net margin of 670.46%. The business's quarterly revenue was down 65.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.62) earnings per share. View The Medicines Company's Earnings History.

When will The Medicines Company make its next earnings announcement?

The Medicines Company is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for The Medicines Company.

Where is The Medicines Company's stock going? Where will The Medicines Company's stock price be in 2017?

10 brokerages have issued twelve-month price targets for The Medicines Company's stock. Their predictions range from $44.00 to $85.00. On average, they expect The Medicines Company's share price to reach $55.44 in the next year. View Analyst Ratings for The Medicines Company.

What are analysts saying about The Medicines Company stock?

Here are some recent quotes from research analysts about The Medicines Company stock:

  • 1. According to Zacks Investment Research, "The Medicines Co. has two potential blockbusters, Inclisiran and Carbavance, in different stages of development. Moreover, divestment of non-core assets to drive shareholder value is encouraging. We are also optimistic about the company’s acquisitions and in-licensing agreements to grow its pipeline. Moreover, the company’s shares have outperformed the industry in the last one year. However, the company is facing generic competition for its flagship product, Angiomax. With Angiomax sales eroding due to the presence of generics, the company’s ability to successfully develop and bring new products to the market is important for growth. Therefore, any regulatory setbacks would weigh heavily on the stock. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (8/8/2017)
  • 2. Jefferies Group LLC analysts commented, " ACC (Mar 17-19) will be a key meeting for inclisiran, where MDCO will detail full 6-mo data for ORION-1 and AMGN will present the FOURIER data. Data from the latter should help guide PIII development for inclisiran, for which MDCO continues to seek a partner. On positive FOURIER results, we lower our risk-discount on inclisiran and our PT increases to $62 (v. $49 prev)." (3/1/2017)

Who are some of The Medicines Company's key competitors?

Who are The Medicines Company's key executives?

The Medicines Company's management team includes the folowing people:

  • Stuart A. Kingsley, President, Chief Operating Officer
  • Clive A. Meanwell M.D. Ph.D., Chief Executive Officer, Director
  • William Bernard O'Connor, Chief Financial Officer
  • Christopher T. Cox, Executive Vice President, Chief Corporate Development Officer
  • Jeffrey Frazier, Executive Vice President, Chief Human Strategy Officer
  • Stephen M. Rodin J.D., General Counsel, Secretary
  • Fredric N. Eshelman Pharm.D., Ph.D., Independent Non-Executive Chairman of the Board
  • Paris Panayiotopoulos, Director
  • William W. Crouse, Independent Director
  • Alexander J. Denner Ph.D., Independent Director

Who owns The Medicines Company stock?

The Medicines Company's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.23%), Vanguard Group Inc. (8.57%), Iridian Asset Management LLC CT (5.17%), Aviva Holdings Ltd. (4.79%), State Street Corp (3.06%) and Westfield Capital Management Co. LP (2.86%). Company insiders that own The Medicines Company stock include Armin M Kessler, Christopher T Cox, Clive Meanwell, Elizabeth H S Wyatt, Fredric N Eshelman, Hiroaki Shigeta, Melvin K Spigelman, Robert G Savage, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines Company.

Who sold The Medicines Company stock? Who is selling The Medicines Company stock?

The Medicines Company's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Aviva Holdings Ltd., Teachers Advisors LLC, First Eagle Investment Management LLC, Elk Creek Partners LLC, Pinnacle Associates Ltd., Parametric Portfolio Associates LLC and Virtu KCG Holdings LLC. View Insider Buying and Selling for The Medicines Company.

Who bought The Medicines Company stock? Who is buying The Medicines Company stock?

The Medicines Company's stock was purchased by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Iridian Asset Management LLC CT, Franklin Resources Inc., Macquarie Group Ltd., State Street Corp, Renaissance Technologies LLC, Creative Planning and Marshall Wace North America L.P.. Company insiders that have bought The Medicines Company stock in the last two years include Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines Company.

How do I buy The Medicines Company stock?

Shares of The Medicines Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines Company's stock price today?

One share of The Medicines Company stock can currently be purchased for approximately $36.20.


MarketBeat Community Rating for The Medicines Company (NASDAQ MDCO)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  327 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  513
MarketBeat's community ratings are surveys of what our community members think about The Medicines Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for The Medicines Company (NASDAQ:MDCO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $55.44 (53.18% upside)

Analysts' Ratings History for The Medicines Company (NASDAQ:MDCO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Chardan CapitalReiterated RatingBuy$85.00LowView Rating Details
9/14/2017Jefferies Group LLCReiterated RatingBuy$54.00LowView Rating Details
8/17/2017Oppenheimer Holdings, Inc.Set Price TargetHold$50.00LowView Rating Details
8/14/2017Citigroup Inc.Lower Price TargetNeutral$45.00 -> $44.00LowView Rating Details
8/10/2017Cowen and CompanyReiterated RatingBuy$61.00 -> $54.00HighView Rating Details
5/23/2017CIBCSet Price Target$50.00MediumView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$60.00HighView Rating Details
3/18/2017J P Morgan Chase & CoReiterated RatingBuyHighView Rating Details
3/1/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
11/18/2016GuggenheimReiterated RatingBuyN/AView Rating Details
11/8/2016Leerink SwannReiterated RatingOutperform$53.00 -> $50.00N/AView Rating Details
7/12/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$28.00 -> $31.00N/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for The Medicines Company (NASDAQ:MDCO)
Earnings by Quarter for The Medicines Company (NASDAQ:MDCO)
Earnings History by Quarter for The Medicines Company (NASDAQ MDCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017($1.37)N/AView Earnings Details
8/9/2017Q2 2017($1.29)($5.52)$29.64 million$18.74 millionViewListenView Earnings Details
4/26/2017Q1 2017($1.13)($1.44)$37.76 million$24.20 millionViewN/AView Earnings Details
2/28/2017Q416($1.43)($1.29)$26.91 million$25.20 millionViewListenView Earnings Details
10/26/2016Q316($1.38)($0.64)$37.26 million$37.60 millionViewListenView Earnings Details
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.90)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.74)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.84)$0.11$188.55 million$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.10)$0.10$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.07)$0.22$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.13)$0.22$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for The Medicines Company (NASDAQ:MDCO)
2017 EPS Consensus Estimate: ($5.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.06)($1.21)
Q2 20173($1.40)($1.10)($1.23)
Q3 20173($1.79)($1.55)($1.65)
Q4 20173($1.33)($1.26)($1.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for The Medicines Company (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for The Medicines Company (NASDAQ:MDCO)
Insider Ownership Percentage: 8.22%
Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
Institutional Ownership by Quarter for The Medicines Company (NASDAQ:MDCO)
Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017William Bernard O'connorCFOSell25,833$46.20$1,193,484.60View SEC Filing  
12/8/2016Christopher T CoxEVPBuy105,500$33.20$3,502,600.00View SEC Filing  
12/8/2016Fredric N EshelmanDirectorBuy621,720$33.77$20,995,484.40View SEC Filing  
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.50View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for The Medicines Company (NASDAQ:MDCO)
Latest Headlines for The Medicines Company (NASDAQ:MDCO)
Source:
DateHeadline
americanbankingnews.com logoThe Medicines Company (MDCO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 24 at 3:10 PM
americanbankingnews.com logoChardan Capital Reaffirms "Buy" Rating for The Medicines Company (MDCO)
www.americanbankingnews.com - September 20 at 8:20 PM
americanbankingnews.com logoZacks: Analysts Anticipate The Medicines Company (MDCO) to Announce -$1.58 EPS
www.americanbankingnews.com - September 17 at 10:30 PM
americanbankingnews.com logoThe Medicines Company (MDCO) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - September 14 at 7:16 PM
finance.yahoo.com logoETFs with exposure to The Medicines Co. : September 13, 2017
finance.yahoo.com - September 14 at 7:36 AM
finance.yahoo.com logoThe Medicines Co. :MDCO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
finance.yahoo.com - September 12 at 12:59 AM
finance.yahoo.com logoThe Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : September 8, 2017
finance.yahoo.com - September 9 at 6:08 AM
feeds.benzinga.com logoTiGenix obtains commercial production license for expanded manufacturing facility
feeds.benzinga.com - September 5 at 1:44 AM
americanbankingnews.com logoThe Medicines Company Expected to Earn Q3 2017 Earnings of ($1.79) Per Share (MDCO)
www.americanbankingnews.com - September 1 at 6:56 AM
americanbankingnews.com logo Brokerages Expect The Medicines Company (MDCO) Will Announce Quarterly Sales of $22.29 Million
www.americanbankingnews.com - September 1 at 5:22 AM
seekingalpha.com logoFDA OKs The Medicines Company's Vabomere antibiotic; shares ahead 6% premarket
seekingalpha.com - September 1 at 3:56 AM
finance.yahoo.com logoThe Medicines Company Announces FDA Approval of VABOMERE™ (meropenem and vaborbactam)
finance.yahoo.com - September 1 at 3:56 AM
finance.yahoo.com logoMedicines Co. shares surge 2.5% on FDA approval of drug for complicated UTIs
finance.yahoo.com - September 1 at 3:56 AM
finance.yahoo.com logoThe Medicines Company's Infection Drug Vabomere Gets FDA Nod
finance.yahoo.com - September 1 at 3:56 AM
finance.yahoo.com logoOppenheimer Comments on The Medicines Company (MDCO) Following FDA Approval for VABOMERE - Yahoo News
finance.yahoo.com - August 31 at 7:09 AM
americanbankingnews.com logoThe Medicines Company (MDCO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 30 at 2:32 PM
feeds.benzinga.com logoMedicines Company Gets FDA Approval, Has 119% Upside According To This Analyst
feeds.benzinga.com - August 30 at 2:20 PM
finance.yahoo.com logoThe Medicines Co. breached its 50 day moving average in a Bullish Manner : MDCO-US : August 29, 2017
finance.yahoo.com - August 30 at 6:28 AM
seekingalpha.com logoMedicines Company up 4.8% amid FDA approval for Vabomere
seekingalpha.com - August 29 at 8:04 PM
americanbankingnews.com logoThe Medicines Company (MDCO) Given New $85.00 Price Target at Chardan Capital
www.americanbankingnews.com - August 29 at 8:40 AM
streetinsider.com logoMedicines Co. (MDCO), Alnylam (ALNY) Announces New, Positive Data from ORION-1 Phase II Study of Inclisiran - StreetInsider.com
www.streetinsider.com - August 28 at 8:21 PM
seekingalpha.com logoAlnylam and The Medicines Company's inclisiran shows significant treatment effect in mid-stage study - Seeking Alpha
seekingalpha.com - August 28 at 8:21 PM
finance.yahoo.com logoNew, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials
finance.yahoo.com - August 28 at 3:20 PM
americanbankingnews.com logoOppenheimer Holdings, Inc. Analysts Give The Medicines Company (MDCO) a $50.00 Price Target
www.americanbankingnews.com - August 19 at 10:54 PM
americanbankingnews.com logoCitigroup Inc. Lowers The Medicines Company (MDCO) Price Target to $44.00
www.americanbankingnews.com - August 14 at 9:52 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for The Medicines Company Reduced by Leerink Swann (MDCO)
www.americanbankingnews.com - August 14 at 2:50 AM
americanbankingnews.com logoOppenheimer Holdings Analysts Boost Earnings Estimates for The Medicines Company (MDCO)
www.americanbankingnews.com - August 14 at 2:50 AM
americanbankingnews.com logoThe Medicines Company Forecasted to Earn Q3 2017 Earnings of ($1.60) Per Share (MDCO)
www.americanbankingnews.com - August 14 at 2:50 AM
americanbankingnews.com logoTheStreet Downgrades The Medicines Company (NASDAQ:MDCO) to D
www.americanbankingnews.com - August 11 at 3:24 PM
americanbankingnews.com logoThe Medicines Company (NASDAQ:MDCO) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 11 at 2:06 PM
streetinsider.com logoThe Medicines Company (MDCO) PT Lowered to $54 at Cowen; Reiterates Outperform
www.streetinsider.com - August 11 at 6:24 AM
americanbankingnews.com logoJefferies Group LLC Reaffirms Buy Rating for The Medicines Company (MDCO)
www.americanbankingnews.com - August 10 at 9:34 PM
americanbankingnews.com logoThe Medicines Company (MDCO) Earns "Buy" Rating from Cowen and Company
www.americanbankingnews.com - August 10 at 2:16 PM
seekingalpha.com logoThe Medicines (MDCO) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 5:01 AM
finance.yahoo.com logoInvestor Network: Medicines Company to Host Earnings Call
finance.yahoo.com - August 10 at 5:01 AM
finance.yahoo.com logoThe Medicines Company Reports Second Quarter 2017 Business and Financial Results
finance.yahoo.com - August 10 at 5:01 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Medicines Co.
finance.yahoo.com - August 10 at 5:01 AM
finance.yahoo.com logoEdited Transcript of MDCO earnings conference call or presentation 9-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 5:01 AM
finance.yahoo.com logoMedicines Co. reports 2Q loss
finance.yahoo.com - August 10 at 5:01 AM
streetinsider.com logoMedicines Company (MDCO) option IV up into Q2 - StreetInsider.com
www.streetinsider.com - August 8 at 11:25 PM
americanbankingnews.com logoThe Medicines Company (NASDAQ:MDCO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 5 at 2:38 PM
americanbankingnews.com logoThe Medicines (NASDAQ:MDCO) and Merus Labs International (MSLI) Head-To-Head Survey
www.americanbankingnews.com - August 5 at 12:46 PM
finance.yahoo.com logoThe Medicines Co. – Value Analysis (NASDAQ:MDCO) : August 5, 2017
finance.yahoo.com - August 5 at 2:38 AM
americanbankingnews.com logoThe Medicines Company (MDCO) to Release Earnings on Wednesday
www.americanbankingnews.com - August 3 at 11:16 AM
seekingalpha.com logoThe Medicines Company Stock Attractively Priced Ahead Of FDA Decision
seekingalpha.com - July 31 at 8:06 PM
finance.yahoo.com logoThe Medicines Company to Announce Second-Quarter 2017 Financial Results on August 9
finance.yahoo.com - July 31 at 8:06 PM
feeds.benzinga.com logoORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017
feeds.benzinga.com - July 28 at 2:42 PM
americanbankingnews.com logoThe Medicines Company (MDCO) PT Raised to $45.00
www.americanbankingnews.com - July 26 at 5:38 PM
americanbankingnews.com logoZacks: Analysts Anticipate The Medicines Company (NASDAQ:MDCO) Will Post Quarterly Sales of $30.51 Million
www.americanbankingnews.com - July 26 at 10:40 AM
seekingalpha.com logoLate-stage study of The Medicines Co's antibiotic combo Vabomere stopped early; U.S. approval likely this quarter; shares ahead 5% premarket
seekingalpha.com - July 26 at 4:48 AM

Social

Chart

The Medicines Company (MDCO) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff